PureTech Health

#ICYMI watch the replay of our CEO, Bharatt Chowrira, and President, Eric Elenko, at the Leerink Partners Global Healthcare Conference. They discussed how our proven R&D model is fueling innovation—plus shared insights into our #IPF program and its potential to transform treatment for this devastating disease. Watch now: https://bit.ly/4iKaork

Our team had the privilege of attending Broadway Belts for PFF, a night of incredible performances in support of the Pulmonary Fibrosis Foundation. We're proud to support this inspiring event and extend our deepest gratitude to the people living with #idiopathicpulmonaryfibrosis, their caregivers, clinical trial investigators, and advocacy groups who are driving progress in #pulmonaryfibrosis research. Together, we're working toward a brighter future for those affected by #IPF and other forms of pulmonary fibrosis.

We’re pleased to welcome Bob Hombach to our Board of Directors and as the Chair of our Audit Committee. He is the former Chief Financial Officer at Baxter (NYSE: BAX), an ~$18 billion company, as well as Baxalta (NYSE: BXLT), a $6 billion company, prior to its acquisition by Shire in 2016. His three decades of experience also includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein (NASDAQ: HSIC), a member of the S&P 500? index. Read the press release: https://bit.ly/4iDs08j

On #InternationalWomensDay, we stand with the International Women's Day 2025 global community to push for meaningful progress toward gender equality. At PureTech, we are committed to advancing women’s participation in biotech, fostering an inclusive workplace, and championing future leaders in science and innovation. This year’s theme, #AccelerateAction, reminds us that equity isn’t just about words—it’s about action. By working together, we can break barriers, drive progress, and create a more inclusive future. As we celebrate the incredible women at PureTech and beyond, we also recognize the importance of inspiring young girls and women to pursue careers in #STEM and leadership. When we take action today, we open doors for the next generation to go even further. #IWD2025?

On #RareDiseaseDay, we stand with the 300 million people worldwide impacted by over 6,000 rare diseases, including idiopathic pulmonary fibrosis (IPF). This year’s theme is #MoreThanYouCanImagine, and it speaks to the unseen challenges faced by the rare disease community, as well as their incredible resilience and strength. At PureTech, our mission is to harness bold scientific ideas to develop groundbreaking therapies. We’re proud to contribute to this effort through our ELEVATE IPF clinical trial program. Late last year, we shared positive data from our Phase 2b trial investigating deupirfenidone, with the potential to become a new standard of care for #IPF patients who have gone over a decade without new treatment options. We are inspired by the courage of families, healthcare professionals, and advocates who work tirelessly to raise awareness and improve the lives of those affected by rare diseases. Together, we’re driving change.

Our CEO, Bharatt Chowrira, Ph.D., J.D., and Co-founder and President, Eric Elenko, Ph.D., will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11th, at 1:00pm EDT https://bit.ly/3EWQDyj

We are thrilled to spotlight the exceptional leadership of David Golod, Ph.D., Head of Clinical Operations and Program Strategy, whose 25+ years in the pharmaceutical industry have been dedicated to advancing clinical programs that bring transformative therapies to patients. David’s expertise and strategic vision have been instrumental in driving the success of our deupirfenidone (LYT-100) and LYT-200 programs, helping bring these innovative treatments closer to those who need them most. With a unique blend of biomedical engineering and pharmaceutical business acumen, he seamlessly integrates patient needs, scientific progress, and business goals to develop strategies that create real impact. His leadership was pivotal in the recent success of our global Phase 2b trial of deupirfenidone for idiopathic pulmonary fibrosis —a multi-year effort that relied on rigorous data collection from nearly 100 clinical trial sites worldwide. Thanks to David and his team’s tireless dedication, we have taken a meaningful step toward potentially changing the standard of care for people with #IPF. David’s unwavering commitment to patient-centered innovation continues to shape our work, ensuring that every step we take is focused on improving lives. #GivingLifeToScience

At PureTech, we are driven by a mission to improve lives, and that extends beyond our therapeutic programs. We’re proud to have partnered with Life Science Cares Boston for their annual Community Coat Drive. Thanks to the generosity of our team, we collected 20 gently used and new coats for children and adults in need. These donations will support HEALTHY WALTHAM, a local organization dedicated to enhancing health and well-being in our community.

This morning our Founded Entity Seaport Therapeutics announced the publication of new research that supports the versality of and innovation behind the Glyph platform https://bit.ly/4aYZI5r

At PureTech, we believe that diverse perspectives fuel bold ideas and lead to transformative innovation. Our commitment to diversity, equity, and inclusion isn’t just a value—it’s a strategic advantage that drives performance, fosters collaboration, and accelerates growth. In 2023, we were recognized for our progress: ?Top 12% within the FTSE250 for surpassing Board and leadership gender balance targets ?Top 30 companies within the FTSE250 for female board membership ?1 of only 8 FTSE250 companies to exceed the 2024 target of more than two minority ethnic directors These milestones aren’t just numbers—they reflect our belief that when we bring together exceptional talent from all backgrounds, we unlock the full potential of our team to innovate and make a meaningful difference in the lives of others. #GivingLifeToScience